SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001720725-22-000051
Filing Date
2022-05-17
Accepted
2022-05-17 17:18:42
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A oysterpoint-2022defa14a.htm DEFA14A 15736
2 image_0.jpg GRAPHIC 494087
3 image_1.jpg GRAPHIC 296939
  Complete submission text file 0001720725-22-000051.txt   1105732
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39112 | Film No.: 22935878
SIC: 2836 Biological Products, (No Diagnostic Substances)